Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:884-890
Published online before print December 22, 2005, doi: 10.1161/01.ATV.0000201064.89581.35
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/4/884    most recent
01.ATV.0000201064.89581.35v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kee, P.
Right arrow Articles by Barter, P.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kee, P.
Right arrow Articles by Barter, P.J.
Related Collections
Right arrowRelated Article
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:884.)
© 2006 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Effect of Inhibiting Cholesteryl Ester Transfer Protein on the Kinetics of High-Density Lipoprotein Cholesteryl Ester Transport in Plasma

In Vivo Studies in Rabbits

P. Kee; D. Caiazza; K.-A. Rye; P.H.R. Barrett; L.A. Morehouse; P.J. Barter

From Royal Adelaide Hospital (P.K.), Adelaide, Australia; The Heart Research Institute (D.C., K.-A.R., P.J.B.), Sydney, Australia; University of Sydney (K.-A.R., P.J.B.), Australia; University of Melbourne (K.-A.R.), Australia; University of Western Australia (P.H.R.B.), Australia; Pfizer Global Research and Development (L.A.M.), Groton, Conn.

Correspondence to Philip Barter, The Heart Research Institute, 145 Missenden Road, Camperdown, New South Wales, Australia 2050. E-mail barterp{at}hri.org.au

Objective— Inhibitors of cholesteryl ester transfer protein (CETP) have been developed as potential anti-atherogenic agents. Theoretically, however, they may be pro-atherogenic by blocking one of the pathways for removing high-density lipoprotein (HDL) cholesteryl esters (CE) from plasma in the final step of reverse cholesterol transport. Here we describe how CETP inhibition in rabbits impacts on the kinetics of HDL CE transport in plasma.

Methods and Results— Administration of a CETP inhibitor reduced CETP activity by 80% to 90% and doubled the HDL cholesteryl ester concentration. Multi-compartmental analysis was used to determine HDL CE kinetics in CETP-inhibited and control rabbits after injection of tracer amounts of both native and reconstituted HDL labeled with 3H in the CE moiety. In control rabbits, HDL CE was removed from plasma by both a direct pathway and an indirect pathway after transfer of HDL CE to the very-low-density lipoprotein/low-density lipoprotein fraction. In CETP-inhibited rabbits there was an almost complete block in removal via the indirect pathway. This did not compromise the overall removal of HDL CE from plasma, which was not different in control and inhibited animals.

Conclusion— Inhibiting CETP in rabbits does not compromise the removal of HDL CE from plasma.

An 80% to 90% inhibition of plasma CETP activity in rabbits doubled the concentration of HDL CE by blocking its transfer to the VLDL/LDL fraction. However, this did not compromise the removal of HDL CE from plasma.


Key Words: cholesteryl esters • high-density lipoprotein • inhibitor • kinetics • reverse cholesterol transport


Related Article:

Cholesteryl Ester Transfer Protein Inhibition: Effect on Reverse Cholesterol Transport?
Patrick C.N. Rensen and Louis M. Havekes
Arterioscler Thromb Vasc Biol 2006 26: 681-684. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
CirculationHome page
S. J. Nicholls, E. M. Tuzcu, D. M. Brennan, J.-C. Tardif, and S. E. Nissen
Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
Circulation, December 9, 2008; 118(24): 2506 - 2514.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
C. C. van der Hoogt, W. de Haan, M. Westerterp, M. Hoekstra, G. M. Dallinga-Thie, J. A. Romijn, H. M. G. Princen, J. W. Jukema, L. M. Havekes, and P. C. N. Rensen
Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression
J. Lipid Res., August 1, 2007; 48(8): 1763 - 1771.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
L. A. Morehouse, E. D. Sugarman, P.-A. Bourassa, T. M. Sand, F. Zimetti, F. Gao, G. H. Rothblat, and A. J. Milici
Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits
J. Lipid Res., June 1, 2007; 48(6): 1263 - 1272.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Westerterp, C. C. van der Hoogt, W. de Haan, E. H. Offerman, G. M. Dallinga-Thie, J. W. Jukema, L. M. Havekes, and P. C.N. Rensen
Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice
Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2552 - 2559.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. C.N. Rensen and L. M. Havekes
Cholesteryl Ester Transfer Protein Inhibition: Effect on Reverse Cholesterol Transport?
Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 681 - 684.
[Full Text] [PDF]